Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Erin M. Bertino

Hematology Oncology | Oncology | Hematology
Ohiohealth Corporation
3595 Olentangy River Rd, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Ohiohealth Corporation
3595 Olentangy River Rd, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Erin Bertino is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. Bertino is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Bertino is currently accepting new patients.

Her clinical research consists of co-authoring 44 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Dublin Methodist Hospital
Grant Medical Center
Riverside Methodist Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

OHIOHEALTH CORPORATION
3595 Olentangy River Rd, Columbus, OH 43214

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung Cancer
An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drugs: Pembrolizumab, Ramucirumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Navitoclax, Osimertinib
Study Phase: Phase 1
Embedded Palliative Care in the Management of Advanced Thoracic Malignancies
Embedded Palliative Care in the Management of Advanced Thoracic Malignancies
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study
Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

44 Total Publications

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.
Journal: Cancer investigation
Published: October 10, 2025
Similar Doctors
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Poongothai K. Sundaram
Hematology Oncology | Oncology | Hematology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Poongothai K. Sundaram
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

3100 Plaza Properties Blvd, 
Columbus, OH 
 (6.1 miles away)
614-383-6000
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients

Poongothai Sundaram is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. Sundaram is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Drug-Induced Thrombocytopenia, and Paget Disease of the Breast. Dr. Sundaram is currently accepting new patients.

Kari Kendra
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kari Kendra
Hematology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kari Kendra
Hematology | Oncology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (2.8 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kari Kendra is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Kendra is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Melanoma, Teratocarcinosarcoma, Olfactory Neuroblastoma, and Merkel Cell Carcinoma.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Peter J. Kourlas
Hematology Oncology | Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Peter J. Kourlas
Hematology Oncology | Hematology | Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (1.9 miles away)
614-442-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Kourlas is a Hematologist Oncology specialist and a Hematologist in Columbus, Ohio. Dr. Kourlas is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Colorectal Cancer, Breast Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Kourlas is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bertino's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 13 Advanced Conditions
View All 90 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile